• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

寻找治疗腹膜胃癌转移的策略:意大利多中心胃癌研究组的分析。

Looking for a strategy in treating peritoneal gastric cancer carcinomatosis: an Italian multicenter Gastric Cancer Research group's analysis.

机构信息

General and Emergency Surgery, Santa Maria della Misericordia Hospital University of Perugia, Perugia, Italy.

General and Upper GI Surgery Division, University of Verona, Verona, Italy.

出版信息

World J Surg Oncol. 2021 Nov 24;19(1):334. doi: 10.1186/s12957-021-02442-9.

DOI:10.1186/s12957-021-02442-9
PMID:34819103
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8611869/
Abstract

BACKGROUND

The present study provides a snapshot of Italian patients with peritoneal metastasis from gastric cancer treated by surgery in Italian centers belonging to the Italian Research Group on Gastric Cancer. Prognostic factors affecting survival in such cohort of patients were evaluated with the final aim to identify patients who may benefit from radical intent surgery.

METHODS

It is a multicentric retrospective study based on a prospectively collected database including demographics, clinical, surgical, pathological, and follow-up data of patients with gastric cancer and synchronous macroscopic peritoneal metastases. Patients were surgically treated from January 2005 to January 2017. We focused on patients with macroscopic peritoneal carcinomatosis (PC) treated with upfront surgery in order to provide homogeneous evidences.

RESULTS

Our results show that patients with peritoneal carcinomatosis cannot be considered all lost. Strictly selected cases (R0/R1 and P1 patients) could benefit from an aggressive surgical approach performing an extended lymphadenectomy and HIPEC treatment.

CONCLUSION

The main result of the study is that GC patients with limited peritoneal involvement can have a survival benefit from a surgery with "radical oncological intent", that means extended lymphadenectomy and R0 resection. The retrospective nature of this study is an important bias, and for this reason, we have started a prospective multicentric study including Italian stage IV patients that hopefully will give us more answers.

摘要

背景

本研究提供了意大利胃癌腹膜转移患者的资料,这些患者在意大利胃癌研究组的意大利中心接受了手术治疗。评估了影响此类患者生存的预后因素,最终目的是确定可能从根治性手术中获益的患者。

方法

这是一项基于前瞻性收集数据库的多中心回顾性研究,该数据库包括胃癌患者的人口统计学、临床、手术、病理和随访数据以及同步性宏观腹膜转移患者的数据。患者于 2005 年 1 月至 2017 年 1 月接受手术治疗。我们主要关注接受根治性手术治疗的有宏观腹膜癌病(PC)的患者,以提供同质的证据。

结果

我们的结果表明,不能认为腹膜转移的患者都失去了希望。严格选择的病例(R0/R1 和 P1 患者)可以从积极的手术方法中获益,进行广泛的淋巴结清扫和 HIPEC 治疗。

结论

该研究的主要结果是,具有有限腹膜受累的 GC 患者可以从具有“根治性肿瘤学意图”的手术中获益,即广泛的淋巴结清扫和 R0 切除。本研究的回顾性性质是一个重要的偏倚,因此,我们已经开始了一项包括意大利 IV 期患者的前瞻性多中心研究,希望能给我们更多的答案。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a557/8611869/ec3997b1f8f0/12957_2021_2442_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a557/8611869/f5c832d81cb4/12957_2021_2442_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a557/8611869/b38efa6522a0/12957_2021_2442_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a557/8611869/2b13e600d663/12957_2021_2442_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a557/8611869/b825dd184386/12957_2021_2442_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a557/8611869/ec3997b1f8f0/12957_2021_2442_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a557/8611869/f5c832d81cb4/12957_2021_2442_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a557/8611869/b38efa6522a0/12957_2021_2442_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a557/8611869/2b13e600d663/12957_2021_2442_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a557/8611869/b825dd184386/12957_2021_2442_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a557/8611869/ec3997b1f8f0/12957_2021_2442_Fig5_HTML.jpg

相似文献

1
Looking for a strategy in treating peritoneal gastric cancer carcinomatosis: an Italian multicenter Gastric Cancer Research group's analysis.寻找治疗腹膜胃癌转移的策略:意大利多中心胃癌研究组的分析。
World J Surg Oncol. 2021 Nov 24;19(1):334. doi: 10.1186/s12957-021-02442-9.
2
Does upfront therapy with cytoreductive surgery and HIPEC confer a survival benefit in patients with synchronous gastric peritoneal carcinomatosis when compared with patients with metachronous gastric peritoneal carcinomatosis?与异时性胃腹膜癌转移患者相比,对于同时性胃腹膜癌转移患者,先行细胞减灭术和腹腔热灌注化疗(HIPEC)治疗是否能带来生存获益?
J BUON. 2017 Sep-Oct;22(5):1144-1147.
3
Preliminary results of prophylactic HIPEC in patients with locally advanced gastric cancer.局部晚期胃癌患者预防性腹腔内热灌注化疗的初步结果
Ann Ital Chir. 2013 Sep-Oct;84(5):551-6.
4
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Gastric Cancer with Peritoneal Carcinomatosis: Multicenter Study of Spanish Group of Peritoneal Oncologic Surgery (GECOP).细胞减灭术和腹腔热灌注化疗(HIPEC)治疗胃癌伴腹膜转移瘤:西班牙腹膜肿瘤外科研讨组(GECOP)的多中心研究。
Ann Surg Oncol. 2019 Aug;26(8):2615-2621. doi: 10.1245/s10434-019-07450-4. Epub 2019 May 21.
5
The 30-year experience-A meta-analysis of randomised and high-quality non-randomised studies of hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer.30年经验——热腹腔内化疗治疗胃癌的随机及高质量非随机研究的荟萃分析
Eur J Cancer. 2017 Jul;79:1-14. doi: 10.1016/j.ejca.2017.03.030. Epub 2017 Apr 26.
6
[Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].1384例腹膜癌病患者接受细胞减灭术加腹腔内热灌注化疗的疗效
Zhonghua Wei Chang Wai Ke Za Zhi. 2021 Mar 25;24(3):230-239. doi: 10.3760/cma.j.cn.441530-20201110-00603.
7
Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with gastric cancer and peritoneal carcinomatosis.细胞减灭术联合腹腔热灌注化疗(HIPEC)治疗胃癌合并腹膜转移患者。
Eur J Surg Oncol. 2018 Nov;44(11):1805-1810. doi: 10.1016/j.ejso.2018.06.036. Epub 2018 Jul 26.
8
Peritoneal carcinomatosis in patients with gastric cancer, and the role for surgical resection, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy.胃癌患者的腹膜癌病,以及手术切除、细胞减灭术和腹腔内热化疗的作用。
Am J Surg. 2014 Jan;207(1):78-83. doi: 10.1016/j.amjsurg.2013.04.010. Epub 2013 Oct 21.
9
Results of systematic second-look surgery plus HIPEC in asymptomatic patients presenting a high risk of developing colorectal peritoneal carcinomatosis.系统二次探查手术联合 HIPEC 治疗无症状且具有结直肠腹膜转移高危因素患者的结果。
Ann Surg. 2011 Aug;254(2):289-93. doi: 10.1097/SLA.0b013e31822638f6.
10
Peritoneal carcinomatosis with synchronous liver metastases from colorectal cancer: Who will benefit from complete cytoreductive surgery?结直肠癌伴腹膜转移及肝同步转移患者:哪些人能从完全肿瘤细胞减灭术中获益?
Int J Surg. 2016 Jan;25:98-105. doi: 10.1016/j.ijsu.2015.11.025. Epub 2015 Dec 1.

引用本文的文献

1
Bidirectional Approach with PIPAC and Systemic Chemotherapy for Patients with Synchronous Gastric Cancer Peritoneal Metastases (GCPM).经腹腔内化疗(PIPAC)联合全身化疗治疗同步胃癌腹膜转移患者的双向策略。
Ann Surg Oncol. 2023 Sep;30(9):5733-5742. doi: 10.1245/s10434-023-13572-7. Epub 2023 Jun 3.
2
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in multimodal therapy for patients with oligometastatic peritoneal gastric cancer: a randomized multicenter phase III trial PIPAC VEROne.寡转移腹膜胃癌患者多模式治疗中的腹腔内加压气雾化疗(PIPAC):一项随机多中心III期试验PIPAC VEROne
Pleura Peritoneum. 2022 Jun 7;7(3):135-141. doi: 10.1515/pp-2022-0111. eCollection 2022 Sep.
3

本文引用的文献

1
Recent Advances in Intra-peritoneal Chemotherapy for Gastric Cancer.胃癌腹腔内化疗的最新进展
J Gastric Cancer. 2020 Jun;20(2):115-126. doi: 10.5230/jgc.2020.20.e15. Epub 2020 Apr 10.
2
Stage IV Gastric Cancer: The Surgical Perspective of the Italian Research Group on Gastric Cancer.IV期胃癌:意大利胃癌研究小组的外科视角
Cancers (Basel). 2020 Jan 9;12(1):158. doi: 10.3390/cancers12010158.
3
Benefits of Surgery After Neoadjuvant Intraperitoneal and Systemic Chemotherapy for Gastric Cancer Patients With Peritoneal Metastasis: A Meta-Analysis.
Clinical significance of initial treatment for peritoneal lavage cytology-positive gastric cancer: outcomes according to treatment strategy.
初始治疗对腹腔灌洗细胞学阳性胃癌的临床意义:根据治疗策略的结果。
World J Surg Oncol. 2022 Feb 15;20(1):35. doi: 10.1186/s12957-022-02512-6.
新辅助腹腔内和全身化疗后胃癌伴腹膜转移患者手术治疗的获益:一项荟萃分析。
J Surg Res. 2020 Jan;245:234-243. doi: 10.1016/j.jss.2019.07.044. Epub 2019 Aug 14.
4
Conversion gastrectomy for stage IV unresectable gastric cancer: a GIRCG retrospective cohort study.四期不可切除胃癌的转化胃切除术:GIRCG 回顾性队列研究。
Gastric Cancer. 2019 Nov;22(6):1285-1293. doi: 10.1007/s10120-019-00968-2. Epub 2019 May 7.
5
Gastric cancer: French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO).胃癌:法国胃肠肿瘤学会临床实践指南——诊断、治疗和随访(SNFGE、FFCD、GERCOR、UNICANCER、SFCD、SFED、SFRO)。
Dig Liver Dis. 2018 Aug;50(8):768-779. doi: 10.1016/j.dld.2018.04.025. Epub 2018 Jun 6.
6
Phase III Trial Comparing Intraperitoneal and Intravenous Paclitaxel Plus S-1 Versus Cisplatin Plus S-1 in Patients With Gastric Cancer With Peritoneal Metastasis: PHOENIX-GC Trial.紫杉醇腹腔内和静脉给药联合 S-1 对比顺铂联合 S-1 治疗胃癌伴腹膜转移患者的 III 期临床试验:PHOENIX-GC 试验。
J Clin Oncol. 2018 Jul 1;36(19):1922-1929. doi: 10.1200/JCO.2018.77.8613. Epub 2018 May 10.
7
Staging laparoscopy for advanced gastric cancer: significance of preoperative clinicopathological factors.进展期胃癌的分期腹腔镜检查:术前临床病理因素的意义
Langenbecks Arch Surg. 2017 Feb;402(1):33-39. doi: 10.1007/s00423-016-1536-7. Epub 2016 Nov 29.
8
The Italian Research Group for Gastric Cancer (GIRCG) guidelines for gastric cancer staging and treatment: 2015.意大利胃癌研究小组(GIRCG)胃癌分期与治疗指南:2015年版
Gastric Cancer. 2017 Jan;20(1):20-30. doi: 10.1007/s10120-016-0615-3. Epub 2016 Jun 2.
9
Factors influencing survival after hepatectomy for metastases from gastric cancer.影响胃癌肝转移切除术后生存的因素。
Eur J Surg Oncol. 2016 Aug;42(8):1229-35. doi: 10.1016/j.ejso.2016.03.030. Epub 2016 Apr 19.
10
Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial.胃切除术加化疗与单纯化疗治疗有单一不可治愈因素的晚期胃癌(REGATTA):一项 3 期随机对照试验。
Lancet Oncol. 2016 Mar;17(3):309-318. doi: 10.1016/S1470-2045(15)00553-7. Epub 2016 Jan 26.